BCR::ABL1-negative myeloproliferative neoplasms in the era of next-generation sequencing

被引：4

作者：

Mroczkowska-Bekarciak, Aleksandra ^{[1
]}

Wrobel, Tomasz ^{[1
]}

机构：

[1] Wroclaw Med Univ, Dept Hematol Blood Neoplasms & Bone Marrow Transpl, Wroclaw, Poland

来源：

FRONTIERS IN GENETICS | 2023年 / 14卷

关键词：

hematooncology; myeloproliferative neoplasms; gene mutations; next-generation sequencing; polycythemia vera; essential thrombocythemia; myelofibrosis; INTERNATIONAL PROGNOSTIC SCORE; JAK2V617F ALLELE BURDEN; TYROSINE KINASE JAK2; NON-DRIVER MUTATIONS; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; PRIMARY MYELOFIBROSIS; THROMBOPOIETIN RECEPTOR; CALRETICULIN MUTATIONS; CALR MUTATIONS;

D O I：

10.3389/fgene.2023.1241912

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

The classical BCR::ABL1-negative myeloproliferative neoplasms such as polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) are clonal diseases with the presence of characteristic "driver mutations" in one of the genes: JAK2, CALR, or MPL. The search for mutations in these three genes is required for the diagnosis of MPNs. Nevertheless, the progress that has been made in the field of molecular genetics has opened a new era in medicine. The search for additional mutations in MPNs is helpful in assessing the risk stratification, disease progression, transformation to acute myeloid leukemia (AML), or choosing the right treatment. In some cases, advanced technologies are needed to find a clonal marker of the disease and establish a diagnosis. This review focuses on how the use of new technologies like next-generation sequencing (NGS) helps in the diagnosis of BCR::ABL1-negative myeloproliferative neoplasms.

引用

页数：11

共 93 条

[81] Targeted deep sequencing in polycythemia vera and essential thrombocythemia [J].

Tefferi, Ayalew ;

Lasho, Terra L. ;

Guglielmelli, Paola ;

Finke, Christy M. ;

Rotunno, Giada ;

Elala, Yoseph ;

Pacilli, Annalisa ;

Hanson, Curtis A. ;

Pancrazzi, Alessandro ;

Ketterling, Rhett P. ;

Mannarelli, Carmela ;

Barraco, Daniela ;

Fanelli, Tiziana ;

Pardanani, Animesh ;

Gangat, Naseema ;

Vannucchi, Alessandro M. .

BLOOD ADVANCES, 2016, 1 (01) :21-30

[82] Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis [J].

Tefferi, Ayalew ;

Guglielmelli, Paola ;

Larson, Dirk R. ;

Finke, Christy ;

Wassie, Emnet A. ;

Pieri, Lisa ;

Gangat, Naseema ;

Fjerza, Rajmonda ;

Belachew, Alem A. ;

Lasho, Terra L. ;

Ketterling, Rhett P. ;

Hanson, Curtis A. ;

Rambaldi, Alessandro ;

Finazzi, Guido ;

Thiele, Juergen ;

Barbui, Tiziano ;

Pardanani, Animesh ;

Vannucchi, Alessandro M. .

BLOOD, 2014, 124 (16) :2507-2513

[83] Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients [J].

Tefferi, Ayalew ;

Wassie, Emnet A. ;

Guglielmelli, Paola ;

Gangat, Naseema ;

Belachew, Alem A. ;

Lasho, Terra L. ;

Finke, Christy ;

Ketterling, Rhett P. ;

Hanson, Curtis A. ;

Pardanani, Animesh ;

Wolanskyj, Alexandra P. ;

Maffioli, Margherita ;

Casalone, Rosario ;

Pacilli, Annalisa ;

Vannucchi, Alessandro M. ;

Passamonti, Francesco .

AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (08) :E121-E124

[84] Development of a Real-Time qPCR Assay for Detection of Common MPL Mutations in Myeloproliferative Neoplasms (MPNS) [J].

Ullah, Naeem ;

Khan, Sadiq Noor ;

Umair, Muhammad ;

Khan, Aamir Ali ;

Liu, Xinhui ;

Khattak, Aamer Ali ;

Yousafzai, Yasar Mehmood .

APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2022, 194 (12) :5907-5917

[85] Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms [J].

Vainchenker, William ;

Kralovics, Robert .

BLOOD, 2017, 129 (06) :667-679

[86] Mutations and prognosis in primary myelofibrosis [J].

Vannucchi, A. M. ;

Lasho, T. L. ;

Guglielmelli, P. ;

Biamonte, F. ;

Pardanani, A. ;

Pereira, A. ;

Finke, C. ;

Score, J. ;

Gangat, N. ;

Mannarelli, C. ;

Ketterling, R. P. ;

Rotunno, G. ;

Knudson, R. A. ;

Susini, M. C. ;

Laborde, R. R. ;

Spolverini, A. ;

Pancrazzi, A. ;

Pieri, L. ;

Manfredini, R. ;

Tagliafico, E. ;

Zini, R. ;

Jones, A. ;

Zoi, K. ;

Reiter, A. ;

Duncombe, A. ;

Pietra, D. ;

Rumi, E. ;

Cervantes, F. ;

Barosi, G. ;

Cazzola, M. ;

Cross, N. C. P. ;

Tefferi, A. .

LEUKEMIA, 2013, 27 (09) :1861-1869

[87] Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations [J].

Verger, Emmanuelle ;

Cassinat, Bruno ;

Chauveau, Aurelie ;

Dosquet, Christine ;

Giraudier, Stephane ;

Schlageter, Marie-Helene ;

Ianotto, Jean-Christophe ;

Yassin, Mohammed A. ;

Al-Dewik, Nader ;

Carillo, Serge ;

Legouffe, Eric ;

Ugo, Valerie ;

Chomienne, Christine ;

Kiladjian, Jean-Jacques .

BLOOD, 2015, 126 (24) :2585-2591

[88] CALR type 1 mutations are associated with an increased incidence of myelofibrosis in young male patients [J].

Weir, Philip ;

Hindley, Andrew ;

Catherwood, Mark ;

McMullin, Mary Frances .

IRISH JOURNAL OF MEDICAL SCIENCE, 2023, 192 (02) :591-593

[89] Next-generation sequencing redefines the diagnosis of triple-negative myeloproliferative neoplasms [J].

Wu, Sanyun ;

Luo, Ping ;

Yu, Yalan ;

Xiong, Bei ;

Wang, Yingying ;

Zuo, Xuelan .

ANNALS OF HEMATOLOGY, 2022, 101 (03) :705-708

[90] Mutational Landscape, Clonal Evolution and Prognostic Effect of Non-Driver Mutations during Disease Progression of Primary Myelofibrosis [J].

Yan, Xin ;

Xu, Zefeng ;

Qu, Shiqiang ;

Qin, Tiejun ;

Huang, Gang ;

Xiao, Zhijian ;

Li, Bing .

BLOOD, 2022, 140 :3965-3966

← 1 2 3 4 5 6 7 8 9 10 →